Capricor Therapeutics (CAPR) Return on Capital Employed (2011 - 2026)
Capricor Therapeutics (CAPR) recorded quarterly Return on Capital Employed of 39.0% in Q1 2026, up 25.93% quarter-over-quarter from 52.66% in Q4 2025, and down 2240.0% on a YoY basis from 1.82% in Q1 2025.
Capricor Therapeutics (CAPR) Return on Capital Employed (2011 - 2026) Analysis & Trends
Capricor Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 39.0% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 2240.0% year-over-year to 39.0%; the TTM figure through Mar 2026 stood at 39.0% (down 2240.0% YoY), while the FY2025 annual figure was 47.56%, down 3848.0% from the prior year.
- Return on Capital Employed was 39.0% for Q1 2026 at Capricor Therapeutics, up from 52.66% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 7.68% in Q4 2024 to a low of 356.58% in Q3 2023.
- Historically, Return on Capital Employed has averaged 102.21% across 5 years, with a median of 80.08% in 2024.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed sank 27119 bps in 2023, then soared 27650 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 104.48% in 2022, then slumped by 38 bps to 144.41% in 2023, then jumped by 95 bps to 7.68% in 2024, then slumped by 586 bps to 52.66% in 2025, then advanced by 26 bps to 39.0% in 2026.
- The last three Return on Capital Employed figures came in at 39.0% (Q1 2026), 52.66% (Q4 2025), and 51.66% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -107.40% |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -50.43% |
| 10 | Capricor Therapeutics | 1.53 Bn | 1.26 Bn | - | -39.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.00% |
| Dec 31, 2025 | -52.66% |
| Sep 30, 2025 | -51.66% |
| Jun 30, 2025 | -34.13% |
| Mar 31, 2025 | -16.61% |
| Dec 31, 2024 | -7.68% |
| Sep 30, 2024 | -80.08% |
| Jun 30, 2024 | -139.51% |
| Mar 31, 2024 | -94.42% |
| Dec 31, 2023 | -144.41% |
| Sep 30, 2023 | -356.58% |
| Jun 30, 2023 | -206.15% |
| Mar 31, 2023 | -202.40% |
| Dec 31, 2022 | -104.48% |
| Sep 30, 2022 | -85.39% |
| Jun 30, 2022 | -61.62% |
| Mar 31, 2022 | -60.84% |
| Dec 31, 2021 | -54.98% |
| Sep 30, 2021 | -48.64% |
| Jun 30, 2021 | -47.55% |